arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2021-27-6-706-712arthyper-2099Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESХимиотерапия как возможный триггер развития липоматоза миокардаChemotherapy as a possible trigger for the myocardial lipomatosis developmenthttps://orcid.org/0000-0002-5383-8355АвагимянА. А.AvagimyanA. A.

 преподаватель кафедры патологической анатомии, ординатор по специальности «Внутренние болезни» 

 Ул. Корьюна 2, Ереван, 0025, Армения 

 MD, Lecturer, Pathological Anatomy Department, Resident in Internal Medicine

 2 Koryun street, Yerevan 0025, Armenia 

dr.ashotavagimyan@gmail.comhttps://orcid.org/0000-0001-5357-1518МкртчянЛ. Г.MkrtchyanL. G.

 кандидат медицинских наук, доцент кафедры кардиологии 

 Ул. Корьюна 2, Ереван, 0025, Армения 

 MD, Head, Cardiology Department 

 2 Koryun street, Yerevan 0025, Armenia 

dr.ashotavagimyan@gmail.comhttps://orcid.org/0000-0003-2473-2444КонончукН. Б.KononchukN. B.

заведующая кардиологическим отделением

 Минск 

 MD, PhD, Head, Department of Cardiology

Minsk 

dr.ashotavagimyan@gmail.comhttps://orcid.org/0000-0001-7896-2080КактурскийЛ. В.KakturskyL. V.

 доктор медицинских наук, профессор, член-корреспондент РАН, научный руководитель 

 Москва 

 MD, PhD, DSc, Professor, Corresponding Member of the Russian Academy of Sciences, Scientific Director

 Moscow 

dr.ashotavagimyan@gmail.comhttps://orcid.org/0000-0003-3186-1797АгатиЛ.AgatiL.

доктор медицинских наук по сердечно-сосудистой медицине, профессор кафедры сердечно-сосудистых, респираторных, нефрологических и гериатрических наук

 Рим 

 MD, PhD in Cardiovascular Medicine, Professor, Department of Cardiovascular, Respiratory, Nephrological and Geriatric Sciences

Rome

dr.ashotavagimyan@gmail.comЕреванский государственный медицинский университет им. М. ГерациАрменияYerevan State Medical University named after M. HeratsiArmeniaГородская клиническая больница скорой медицинской помощи МинскаБеларусьCity Clinical Emergency HospitalBelarusФедеральное государственное бюджетное научное учреждение «Научно-исследовательский институт морфологии человека»РоссияResearch Institute of Human MorphologyRussian FederationСапиенца — Римский университетИталияSapienza — University of RomeItaly202118032022276706712Copyright © Авагимян А.А., Мкртчян Л.Г., Конончук Н.Б., Кактурский Л.В., Агати Л., 20222022Авагимян А.А., Мкртчян Л.Г., Конончук Н.Б., Кактурский Л.В., Агати Л.Avagimyan A.A., Mkrtchyan L.G., Kononchuk N.B., Kaktursky L.V., Agati L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/2099

 В настоящей статье представлен клинический пример асимптоматической дезорганизации миокарда, ассоциированной с приемом препаратов химиотерапевтического ряда. Описывается развитие липоматоза миокарда у пациентки 23 лет, страдающей раком правой молочной железы, прошедшей 4 цикла химиотерапии АС  режима и скончавшейся от разрыва мешотчатой аневризмы внутренней  сонной артерии размером 14 см. В данной статье представлены как  данные инструментально-лабораторных исследований, так и патоморфологического анализа. 

 This article presents a clinical case of an asymptomatic myocardial damage associated with the chemotherapy. Myocardial lipomatosis developed in a 23-year-old patient with cancer of the right breast after 4 AC chemotherapy cycles. The death resulted from the rupture of a 14 cm saccular aneurysm of the internal carotid artery. This article presents both the data of instrumental and laboratory tests and pathomorphological analysis. 

кардиоонкологияхимиотерапиялипоматозcardiooncologychemotherapylipomatosisReferencesAnker MS, Lena A, Hadzibegovic S, Belenkov Y, Bergler-Klein J, A de Boer R et al. Modern-day cardio-oncology: a report from the 'Heart Failure and World Congress on Acute Heart Failure 2018. ESC Heart Fail. 2018;5(6):1083–1091.Anker MS, Lena A, Hadzibegovic S, Belenkov Y, Bergler-Klein J, A de Boer R et al. Modern-day cardio-oncology: a report from the 'Heart Failure and World Congress on Acute Heart Failure 2018. ESC Heart Fail. 2018;5(6):1083–1091.Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26. doi:10.3389/fcvm.2020.00026Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26. doi:10.3389/fcvm.2020.00026Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945–1960. doi:10.1002/ejhf.1920Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945–1960. doi:10.1002/ejhf.1920Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22(11):1966–1983. doi:10.1002/ejhf.2017Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22(11):1966–1983. doi:10.1002/ejhf.2017Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32(2):302–14. doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32(2):302–14. doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A et al. ESMO Guidelines Committee. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–190. doi:10.1016/j.annonc.2019.10.023Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A et al. ESMO Guidelines Committee. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–190. doi:10.1016/j.annonc.2019.10.023López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41(18):1720–1729. doi:10.1093/eurheartj/ehaa006López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41(18):1720–1729. doi:10.1093/eurheartj/ehaa006Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971–977. doi:10.1136/heartjnl-2017-312103Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971–977. doi:10.1136/heartjnl-2017-312103Renu K, Abilash V G, Tirupathi Pichiah PB, Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy — an update. Eur J Pharmacol. 2018;818:241–253. doi:10.1016/j.ejphar.2017.10.043Renu K, Abilash V G, Tirupathi Pichiah PB, Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy — an update. Eur J Pharmacol. 2018;818:241–253. doi:10.1016/j.ejphar.2017.10.043Avagimyan A, Kakturskiy L, Heshmat-Ghahdarijani K, Pogosova N, Sarrafzadegan N. Anthracycline associated disturbances of cardiovascular homeostasis. Current Problems in Cardiology. 2021;100909. doi:10.1016/j.cpcardiol.2021.100909Avagimyan A, Kakturskiy L, Heshmat-Ghahdarijani K, Pogosova N, Sarrafzadegan N. Anthracycline associated disturbances of cardiovascular homeostasis. Current Problems in Cardiology. 2021;100909. doi:10.1016/j.cpcardiol.2021.100909Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85(3):1093–1129. doi:10.1152/physrev.00006.2004Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85(3):1093–1129. doi:10.1152/physrev.00006.2004Taegtmeyer H, Lam T, Davogustto G. Cardiac metabolism in perspective. Compr Physiol. 2016;6(4):1675–1699. doi:10.1002/cphy.c150056Taegtmeyer H, Lam T, Davogustto G. Cardiac metabolism in perspective. Compr Physiol. 2016;6(4):1675–1699. doi:10.1002/cphy.c150056

The authors declare that there are no conflicts of interest present.